Journal of Clinical Oncology
Articles in this Issue
Comprehensive genomic alterations identification and potential shared neoantigens for non-small cell lung cancer immunotherapy.
e20582 Background: Despite advances in therapies, the development of drug resistance in non-small cell lung cancer (NSCLC) poses a significant challenge....
OPERETTA: A phase II study evaluating neoadjuvant and adjuvant olaparib plus pembrolizumab following platinum-based chemotherapy plus pembrolizumab for germline BRCA mutated triple negative breast cancer.
TPS632 Background: Triple negative breast cancer (TNBC) remains the most challenging phenotype of breast cancer. There is still an unmet clinical need for...
Survival outcomes and therapy response in <i>RAS</i> -mutated myeloid malignancies.
e18515 Background: RAS proteins are GTP-binding proteins that act as molecular switches to regulate cell signal transduction. Mutations in these proteins...
Post-neoadjuvant imaging for prediction of pathologic complete response to KEYNOTE 522 in patients with early triple-negative breast cancer.
e13153 Background: The KEYNOTE 522 trial established the role of neoadjuvant chemotherapy with pembrolizumab in patients with clinical stage II-III triple...
Breast cancer post-ovarian cancer in germline non-BRCA homologous recombination (HR) gene pathogenic variant carriers.
10607 Background: Ovarian cancer (OC) is characterized by deficiencies in homologous recombination (HR). Although germline and somatic BRCA1/2...
Kaleido registry: A multi-center registry platform with site staff and automation to enable accelerated clinical research and drug development at scale in community practices.
11020 Background: The number of candidate drugs and clinical trials in oncology is rapidly increasing, necessitating innovative approaches to streamline p...
Spatial transcriptomics for profiling the microenvironment of cervical precancer progression from routine H&E slides: Applications for pharmaceutical development.
e17536 Background: High-grade cervical intraepithelial neoplasia (HG-CIN) affects 200,000 U.S. women annually, with rising prevalence among those aged 30...
Validation of an optimized tissue-agnostic genome-wide methylome enrichment assay to predict clinical outcomes in patients treated with pembrolizumab.
2545 Background: Recent work from the INSPIRE study (PMID38393391) suggests that kinetics of cell-free DNA (cfDNA) methylation profiles reflect immunother...
Utidelone in combination with etoposide and bevacizumab in HER2-negative breast cancer patients with brain metastasis: A prospective, single-arm, phase II trial.
2012 Background: For advanced HER2 negative breast cancer patients with brain metastasis, systematic therapy has failed to yield satisfied efficacy, altho...
Pathologic complete response and breast cancer survival post-neoadjuvant chemotherapy: A systematic review and meta-analysis of real-world data.
e12625 Background: Breast cancer is the most frequently diagnosed cancer and a major cause of cancer mortality among women worldwide. Neoadjuvant chemothe...
Multi-omics analysis of PD-1 inhibitor combination in neoadjuvant treatment of pMMR/MSS rectal cancer: Insights from the PANFORTE trial.
e14613 Background: Programmed cell death-1 (PD-1) antibody monotherapy has shown limited effectiveness for proficient mismatch repair or microsatellite st...
Financial hardship and non-adherence to lifestyle and surveillance recommendations in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).
10068 Background: The association between different aspects of medical financial hardship and non-adherence to healthy lifestyle recommendations and surve...
Updated results of a phase II study of RC48 in combination with tislelizumab as pre-transurethral resection neoadjuvant therapy for extensive high-risk non–muscle-invasive bladder cancer with HER2 overexpression.
e16596 Background: The combination of antibody-drug conjugates and immune checkpoint inhibitors has shown promising results in patients with advanced and...
Single-cell analysis and histopathological evaluation of tertiary lymphoid structures and association with survival in melanoma.
e21509 Background: Tertiary lymphoid structures (TLS) are transient ectopic lymphoid aggregates composed of immune cells such as B cells, T cells, and den...
The emerging role of pharmacists in optimizing therapeutic substitutions within the US Oncology network.
e13565 Background: Community oncology practices bridge the gap between the growing disparity of increased cancer incidence in rural areas and a declining...
Results of a phase I study of alpelisib and sacituzumab govitecan (SG) in patients with HER2-negative metastatic breast cancer (MBC).
1094 Background: Sacituzumab govitecan (TROP2-directed antibody drug conjugate, ADC) is effective in treatment of pretreated HER2-negative MBC. PI3K is th...
Awareness of gestational surrogacy among female patients treated for cancer: A national survey.
12103 Background: ASCO and other international guidelines recommend fertility counseling at diagnosis for all reproductive-aged cancer patients. Yet, how...
Acoustic biomarkers and AI: Transforming NSCLC detection and personalized care.
1568 Background: Implementing a mass screening program for lung cancer using low-dose chest CT presents significant challenges, including financial constr...
Racial differences in the association between agent orange exposure and the progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US Veterans.
10555 Background: Agent Orange (AO), an herbicide used during the Vietnam War Era (1/9/1962-5/7/1975), is implicated in myelomagenesis due to 2,3,7,8-tetr...
Metaplastic breast cancer: Clinical and prognostic features.
e13163 Background: Metaplastic breast cancer (MpBC) is a rare, aggressive malignancy characterized by differentiation of neoplastic epithelium into epithe...
Phase I study of induction chemoimmunotherapy (ICI) with cemiplimab in combination with cisplatin and docetaxel (TPI) in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).
e18116 Background: To enhance patients' quality of life and prolong their survival, exploring an effective, low-toxicity version of the induction regimen...
Preoperative steroid for enhancing patients’ recovery after head and neck cancer surgery with free tissue transfer reconstruction: Phase III, placebo-controlled, randomized, double-blind study (J-SUPPORT 2022, PreSte-HN Study).
6072 Background: The enhanced recovery after surgery (ERAS) pathway integrates evidence-based protocols to optimize recovery during the perioperative peri...
Blastic plasmacytoid dendritic cell neoplasm (BPDCN): Prognostic factors and outcomes in 68 Mayo Clinic patients.
e18508 Background: BPDCN is a rare and aggressive hematologic malignancy. Despite the advent of targeted therapies, median overall survival (mOS) remains...
Real-world comparative outcomes of alectinib and brigatinib in ALK-positive non–small cell lung cancer: A retrospective cohort analysis using HIRA data.
8608 Background: Alectinib and brigatinib are both recommended as first-line treatments for patients with ALK-positive non–small cell lung cancer (NSCLC)....
Outcomes of additional BCG versus sequential gemcitabine + docetaxel in BCG-exposed high-risk non–muscle-invasive bladder cancer.
e16600 Background: For BCG-exposed high-risk (HR) non-muscle-invasive bladder cancer (NMIBC), current standard of care encompasses additional BCG treatmen...